AR042148A1 - Derivados de indazol como antagonistas de crf - Google Patents
Derivados de indazol como antagonistas de crfInfo
- Publication number
- AR042148A1 AR042148A1 ARP030104398A ARP030104398A AR042148A1 AR 042148 A1 AR042148 A1 AR 042148A1 AR P030104398 A ARP030104398 A AR P030104398A AR P030104398 A ARP030104398 A AR P030104398A AR 042148 A1 AR042148 A1 AR 042148A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- cycloalkyl
- alkoxy
- group
- aryl
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title abstract 2
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical class C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 title 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 15
- 125000001072 heteroaryl group Chemical group 0.000 abstract 13
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 12
- 125000000217 alkyl group Chemical group 0.000 abstract 12
- 125000003118 aryl group Chemical group 0.000 abstract 12
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 10
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 10
- 125000001424 substituent group Chemical group 0.000 abstract 10
- 125000001188 haloalkyl group Chemical group 0.000 abstract 9
- 229910052736 halogen Inorganic materials 0.000 abstract 9
- 150000002367 halogens Chemical class 0.000 abstract 9
- 229910052739 hydrogen Inorganic materials 0.000 abstract 8
- 239000001257 hydrogen Substances 0.000 abstract 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 8
- 125000006545 (C1-C9) alkyl group Chemical group 0.000 abstract 7
- 150000001875 compounds Chemical class 0.000 abstract 7
- 125000000623 heterocyclic group Chemical group 0.000 abstract 7
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 7
- 125000003282 alkyl amino group Chemical group 0.000 abstract 6
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Chemical group C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 abstract 6
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 5
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 5
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical group C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 abstract 4
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical group C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 abstract 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 abstract 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical group C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 abstract 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical group C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 abstract 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical group C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 abstract 4
- 125000002252 acyl group Chemical group 0.000 abstract 4
- 125000004442 acylamino group Chemical group 0.000 abstract 4
- 125000004103 aminoalkyl group Chemical group 0.000 abstract 4
- 125000005097 aminocarbonylalkyl group Chemical group 0.000 abstract 4
- -1 aminocarbonylamino, aminosulfonyl Chemical group 0.000 abstract 4
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 4
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 4
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 abstract 4
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 abstract 3
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 125000003277 amino group Chemical group 0.000 abstract 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 3
- 125000004415 heterocyclylalkyl group Chemical group 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 125000003884 phenylalkyl group Chemical group 0.000 abstract 3
- 125000004001 thioalkyl group Chemical group 0.000 abstract 3
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 abstract 2
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 abstract 2
- OTPDWCMLUKMQNO-UHFFFAOYSA-N 1,2,3,4-tetrahydropyrimidine Chemical group C1NCC=CN1 OTPDWCMLUKMQNO-UHFFFAOYSA-N 0.000 abstract 2
- DKYBVKMIZODYKL-UHFFFAOYSA-N 1,3-diazinane Chemical group C1CNCNC1 DKYBVKMIZODYKL-UHFFFAOYSA-N 0.000 abstract 2
- VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical group C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 abstract 2
- 229910003827 NRaRb Inorganic materials 0.000 abstract 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical group C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 abstract 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 2
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 abstract 2
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 abstract 2
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical group C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 abstract 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 2
- 125000004181 carboxyalkyl group Chemical group 0.000 abstract 2
- 125000004966 cyanoalkyl group Chemical group 0.000 abstract 2
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical group C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 125000002757 morpholinyl group Chemical group 0.000 abstract 2
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 125000004043 oxo group Chemical group O=* 0.000 abstract 2
- 125000004193 piperazinyl group Chemical group 0.000 abstract 2
- 125000003386 piperidinyl group Chemical group 0.000 abstract 2
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical group C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 101000957724 Catostomus commersonii Corticoliberin-1 Proteins 0.000 abstract 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 1
- 125000004472 dialkylaminosulfonyl group Chemical group 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000004404 heteroalkyl group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se refiere a compuestos que son en general antagonistas de receptores del factor CRF-1 y que se ajustan a la fórmula (1) o a la fórmula (2), en la que R3 es arilo o heteroarilo eventualmente sustituido, R1 y R2 tienen el significado definido en la descripción; o isómeros individuales, mezclas racémicas o no racémicas de isómeros o sales farmacéuticamente aceptables de los mismos. La presente se refiere además a procesos para obtener dichos compuestos, a composiciones farmacéuticas que contienen tales compuestos y a métodos para su utilización como agentes terapéuticos. Reivindicación 1: Un compuesto de la fórmula (1) o (2) en la que: R2 es hidrógeno, alquilo C1-6, cicloalquilo C3-6, (cicloalquil C3-6)-alquilo C1-3, (alquil C1-6)carbonilo, alquilsulfonilo C1-6, arilo o arilalquilo, en la que dicho arilo o arilalquilo está eventualmente sustituido por uno o varios sustituyentes elegidos con independencia entre sí entre alquilo C1-6, haloalquilo, alcoxi C1-6 y halógeno; R3 es arilo o heteroarilo, cada uno de ellos eventualmente sustituido por uno o varios sustituyentes elegidos con independencia entre sí entre el grupo formado por alquilo C1-6, alcoxi C1-6, alquiltio C1-6, alquilsulfonilo C1-6, aminosulfonilo, monoalquilaminosulfonilo, dialquilaminosulfonilo, halógeno, haloalquilo, ciano, nitro, -NRa''Rb'', en el que Ra'' y Rb'' se eligen con independencia entre sí entre hidrógeno, alquilo C1-9 y (alquil C1-9)carbonilo; R1 en el caso de los compuestos de formula (1) es -NRaRb, -CRcRdRe, CO2Ra o -C(O)NRaRa; o en el caso de los compuestos de la fórmula (2) es -NRaRb, -CRcRdRe, CO2Ra; o, en el caso de los compuestos de la fórmula (1) o (2) es hidrógeno, cicloalquenilo, arilo o heteroarilo, en el que cada arilo o heteroarilo está eventualmente sustituido por uno o varios sustituyentes elegidos con independencia entre sí entre alquilo C1-6, alcoxi C1-6, alquiltio C1-6, alquilsulfonilo C1-6, halógeno, haloalquilo, ciano, nitro, -C(O)NRa'Rb' y -NRa'Rb', en el que Ra' y Rb' se eligen con independencia entre sí entre hidrógeno, alquilo C1-9, y (alquil C1-9)carbonilo; Ra y Rb se eligen con independencia entre sí entre hidrógeno, alquilo C1-9, hidroxialquilo, (alcoxi C1-6)alquilo, (alquil C1-6)tioalquilo, carboxialquilo, acilo, cicloalquilo C3-6, (cicloalquil C3-6)-alquilo C1-3, di-(cicloalquil C3-6)-alquilo C1-3, heteroalquilo C1-6, aminoalquilo, aminocarbonilalquilo, cianoalquilo, heterociclilo C5-8, heterociclilalquilo, arilo, arilalquilo, heteroarilo, heteroarilalquilo, fenilalquilo, difenilalquilo y alquilo C1-3 sustituidos por un grupo cicloalquilo C3-6 y un grupo fenilo, en el que cada uno de dichos cicloalquilo, fenilo o heteroarilo está eventualmente sustituido por uno o varios sustituyentes elegidos con independencia entre sí entre el grupo formado por alquilo C1-6, haloalquilo, alcoxi C1-6, amino, alquilamino, dialquilamino, hidroxialquilo, ciano, acilamino, alquilsulfonilo, alquilsulfoniloxi y halógeno y cada uno de dichos grupos amino está eventualmente monosustituido o disustituido por alquilo; o Ra y Rb junto con el átomo de nitrógeno al que están unidos forman un anillo heterociclilo o heteroarilo elegido entre el grupo formado por pirrolidina, piperidina, homopiperidina, tetrahidropiridina, 1,2,3,4-tetrahidroquinolina, 1,2,3,4-tetrahidroisoquinolina, tetrahidropirimidina, hexahidropirimidina, pirazolidina, piperazina, morfolina, imidazolina, pirrol, pirazol e imidazol, en el que cada uno de dichos anillos está eventualmente sustituido por uno o varios sustituyentes elegidos entre el grupo formado por hidroxi, oxo, alquilo, hidroxialquilo, alcoxi, alcoxialquilo, aminoalquilo, acilo, acilamino, aminocarbonilo, aminocarbonilalquilo, aminocarbonilamino, aminosulfonilo, alquilsulfonilamino, aminosulfonilamino y fenilo, en el que cada uno de dichos grupos fenilo está eventualmente sustituido por uno o varios sustituyentes elegidos con independencia entre sí entre alquilo C1-6, haloalquilo, alcoxi C1-6, amino, alquilamino, dialquilamino y halógeno y cada uno de dichos grupos amino está eventualmente monosustituido o disustituido por alquilo o está contenido en un grupo pirrolidinilo, piperidinilo, morfolinilo o piperazinilo; Rc es hidrógeno, hidroxi, alcoxi C1-6 o -NRa'''Rb'''; Rd y Re se eligen con independencia entre sí entre hidrógeno, alquilo C1-9, hidroxialquilo, (alcoxi C1-6)alquilo, (alquil C1-6)tioalquilo, heteroalquilo, heterociclilo, heterociclilalquilo, cicloalquilo C3-6, (cicloalquil C3-6)-alquilo C1-3, di(cicloalquil C3-6)-alquilo C1-3, arilo, arilalquilo, heteroarilo, heteroarilalquilo, fenilalquilo, difenil-alquilo C1-3 y alquilo C1-3 sustituidos por un grupo cicloalquilo C3-6 y un grupo fenilo, en el que cada uno de dichos grupos cicloalquilo, fenilo, arilo o heteroarilo está eventualmente sustituido por uno o varios sustituyentes elegidos con independencia entre sí entre el grupo formado por alquilo C1-6, haloalquilo, alcoxi C1-6, amino, alquilamino, dialquilamino y halógeno; o Rc y Rd juntos forman un grupo divalente elegido entre alquilidenilo C1-6, heteroalquilidenilo C1-6, cicloalquilidenilo C3-6, (cicloalquil C3-6)-alquilidenilo, (cicloalquil C3-6)-(alquil C1-3)-alquilidenilo, heterociclilidenilo C3-6, (heterociclil C3-6)-alquilidenilo C1-3, (heterociclilalquil C3-6)-alquilidenilo C1-3, aril-alquilidenilo C1-3, aril-(alquil C1-3)- alquilidenilo, heteroaril-alquilidenilo C1-3 y heteroarilalquil-alquilidenilo C1-3, en el que cada uno de dichos grupos cicloalquilo, arilo o heteroarilo está eventualmente sustituido por uno o varios sustituyentes elegidos con independencia entre sí entre alquilo C1-6, haloalquilo, alcoxi C1-6, amino, alquilamino, dialquilamino y halógeno; o Rd y Re junto con el átomo de carbono al que están unidos forman un anillo cicloalquilo o heterociclilo; Ra''' y Rb''' se eligen con independencia ente sí entre hidrógeno, alquilo C1-9, hidroxialquilo, (alcoxi C1-6)alquilo, (alquil C1-6)tioalquilo, carboxialquilo, acilo, cicloalquilo C3-6, (cicloalquil C3-6)-alquilo C1-3, di-(cicloalquil C3-6)-alquilo C1-3, heteroalquilo C1-6, aminoalquilo, aminocarbonilalquilo, cianoalquilo, heterociclilo C5-8, heterociclilalquilo, arilo, arilalquilo, heteroarilo, heteroarilalquilo, fenilalquilo, difenil-alquilo C1-3 y alquilo C1-3 sustituidos por un grupo cicloalquilo C3-6 y un grupo fenilo, en el que cada uno de dichos grupos cicloalquilo, fenilo, arilo o heteroarilo está eventualmente sustituido por uno o varios sustituyentes elegidos con independencia entre sí entre el grupo formado por alquilo C1-6, haloalquilo, alcoxi C1-6, amino, alquilamino, dialquilamino, hidroxialquilo, ciano, acilamino, alquilsulfonilo, alquilsulfoniloxi y halógeno y cada uno de dichos grupos amino está eventualmente monosustituido o disustituido por alquilo; o Ra''' y Rb''' junto con el átomo de nitrógeno al que están unidos forman un anillo heterociclilo o heteroarilo elegido entre el grupo formado por pirrolidina, piperidina, homopiperidina, tetrahidropiridina, 1,2,3,4-tetrahidroquinolina, 1,2,3,4-tetrahidroisoquinolina, tetrahidropirimidina, hexahidropirimidina, pirazolidina, piperazina, morfolina, imidazolina, pirrol, pirazol e imidazol, en el que cada uno de dichos anillos está eventualmente sustituido por uno o varios sustituyentes elegidos entre el grupo formado por hidroxi, oxo, alquilo, hidroxialquilo, alcoxi, alcoxialquilo, aminoalquilo, acilo, acilamino, aminocarbonilo, aminocarbonilalquilo, aminocarbonilamino, aminosulfonilo, alquilsulfonilamino, aminosulfonilamino y fenilo, en el que cada uno de dichos grupos fenilo está eventualmente sustituido por uno o varios sustituyentes elegidos con independencia entre sí entre alquilo C1-6, haloalquilo, alcoxi C1-6, amino, alquilamino, dialquilamino y halógeno y cada uno de dichos grupos amino está eventualmente monosustituido o disustituido por alquilo o está contenido en un grupo pirrolidinilo, piperidinilo, morfolinilo o piperazinilo; o isómeros individuales, mezclas racémicas o no racémicas de isómeros o sales farmacéuticamente aceptables de los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43016802P | 2002-12-02 | 2002-12-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR042148A1 true AR042148A1 (es) | 2005-06-08 |
Family
ID=32469420
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030104398A AR042148A1 (es) | 2002-12-02 | 2003-11-28 | Derivados de indazol como antagonistas de crf |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US7214699B2 (es) |
| EP (1) | EP1569911B1 (es) |
| JP (1) | JP4401298B2 (es) |
| KR (1) | KR100761562B1 (es) |
| CN (1) | CN100439341C (es) |
| AR (1) | AR042148A1 (es) |
| AT (1) | ATE399768T1 (es) |
| AU (1) | AU2003286180B2 (es) |
| BR (1) | BR0316950A (es) |
| CA (1) | CA2507074A1 (es) |
| DE (1) | DE60321958D1 (es) |
| ES (1) | ES2309368T3 (es) |
| GT (1) | GT200300263A (es) |
| MX (1) | MXPA05005794A (es) |
| PA (1) | PA8589601A1 (es) |
| PE (1) | PE20040764A1 (es) |
| PL (1) | PL377609A1 (es) |
| RU (1) | RU2341518C2 (es) |
| TW (1) | TW200418816A (es) |
| UY (1) | UY28105A1 (es) |
| WO (1) | WO2004050634A1 (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| DE602004025354D1 (de) * | 2003-08-14 | 2010-03-18 | Hoffmann La Roche | Gabanerge modulatoren |
| US6984652B2 (en) * | 2003-09-05 | 2006-01-10 | Warner-Lambert Company Llc | Gyrase inhibitors |
| GB0400895D0 (en) * | 2004-01-15 | 2004-02-18 | Smithkline Beecham Corp | Chemical compounds |
| AR050253A1 (es) * | 2004-06-24 | 2006-10-11 | Smithkline Beecham Corp | Compuesto derivado de indazol carboxamida, composicion que lo comprende y su uso para la preparacion de un medicamento |
| AU2005271737A1 (en) * | 2004-08-03 | 2006-02-16 | Wyeth | Indazoles useful in treating cardiovascular diseases |
| CN100516049C (zh) * | 2004-11-16 | 2009-07-22 | 永信药品工业股份有限公司 | 抗血管生成药n2-(取代的芳基甲基)-3-(取代的苯基)吲唑的合成 |
| US8063071B2 (en) | 2007-10-31 | 2011-11-22 | GlaxoSmithKline, LLC | Chemical compounds |
| CN101466703A (zh) * | 2006-04-11 | 2009-06-24 | 弗·哈夫曼-拉罗切有限公司 | 杂环GABA-α亚型选择性受体调节剂 |
| ITMI20062230A1 (it) | 2006-11-22 | 2008-05-23 | Acraf | Composto 2-alchil-indazolico procedimento per preparalo e composizione farmaceutica che lo comprende |
| PE20081889A1 (es) | 2007-03-23 | 2009-03-05 | Smithkline Beecham Corp | Indol carboxamidas como inhibidores de ikk2 |
| MX2009013293A (es) | 2007-06-04 | 2010-02-15 | Synergy Pharmaceuticals Inc | Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos. |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| EP2810951B1 (en) | 2008-06-04 | 2017-03-15 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| CA2730603C (en) | 2008-07-16 | 2019-09-24 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| US8273900B2 (en) | 2008-08-07 | 2012-09-25 | Novartis Ag | Organic compounds |
| WO2012026511A1 (ja) * | 2010-08-27 | 2012-03-01 | 協和発酵キリン株式会社 | 医薬組成物 |
| JP2016514671A (ja) | 2013-03-15 | 2016-05-23 | シナジー ファーマシューティカルズ インコーポレイテッド | グアニル酸シクラーゼのアゴニストおよびその使用 |
| JP2016514670A (ja) | 2013-03-15 | 2016-05-23 | シナジー ファーマシューティカルズ インコーポレイテッド | 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト |
| WO2016014904A1 (en) | 2014-07-24 | 2016-01-28 | Beta Pharma, Inc. | 2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof |
| KR101713303B1 (ko) * | 2015-12-24 | 2017-03-07 | 강원대학교산학협력단 | 2ｈ-인다졸 유도체의 제조방법 |
| WO2022107064A1 (en) | 2020-11-20 | 2022-05-27 | Idemitsu Kosan Co., Ltd. | Heterocyclic compound and an organic electroluminescence device comprising the heterocyclic compound |
| CN113831319A (zh) * | 2021-10-19 | 2021-12-24 | 北京科技大学 | 含有大位阻取代基芳基硼酸/硼酸酯的铃木反应方法 |
| KR20230081778A (ko) | 2021-11-29 | 2023-06-08 | 조이운 | VOCs 저감장치 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6005109A (en) * | 1997-10-30 | 1999-12-21 | Pflizer Inc. | Pyrazoles and pyrazolopyrimidines having CRF antagonistic activity |
| US5712303A (en) * | 1992-12-17 | 1998-01-27 | Pfizer Inc. | Pyrazoles and pyrazolopyrimidines having CRF antagonistic activity |
| FR2701026B1 (fr) * | 1993-02-02 | 1995-03-31 | Adir | Nouveaux dérivés de l'indole, de l'indazole et du benzisoxazole, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent. |
| US5705646A (en) * | 1993-09-30 | 1998-01-06 | Pfizer Inc. | Substituted pyrazoles as CRF antagonists |
| US5668145A (en) * | 1993-11-12 | 1997-09-16 | Pfizer Inc. | Amino-substituted pyrazoles having CRF antagonistic activity |
| US5646152A (en) * | 1994-06-15 | 1997-07-08 | Pfizer Inc. | Methods of administering CRF antagonists |
| US5760225A (en) * | 1996-11-15 | 1998-06-02 | Neurogen Corporation | Certain pyrazole derivatives as corticotropin-releasing factor receptor CRF1 specific ligands |
| PL340753A1 (en) | 1997-11-04 | 2001-02-26 | Pfizer Prod Inc | Substitution of indazolic bioisoster for cathechol in therapeutically active compounds |
| GB9824310D0 (en) * | 1998-11-05 | 1998-12-30 | Univ London | Activators of soluble guanylate cyclase |
| AU2001234958A1 (en) * | 2000-02-11 | 2001-08-20 | Bristol-Myers Squibb Company | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases |
| CA2413002A1 (en) * | 2000-06-30 | 2002-12-19 | Banyu Pharmaceutical Co., Ltd. | Novel pyrazinone derivatives |
| US6897231B2 (en) * | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
| WO2002016348A1 (en) * | 2000-08-09 | 2002-02-28 | Astrazeneca Ab | Antiangiogenic bicyclic derivatives |
| JP2005507922A (ja) * | 2001-09-19 | 2005-03-24 | ファルマシア・コーポレイション | 炎症の治療のための置換されたインダゾール化合物 |
| FR2836915B1 (fr) * | 2002-03-11 | 2008-01-11 | Aventis Pharma Sa | Derives d'aminoindazoles, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant |
| TW200409759A (en) * | 2002-09-25 | 2004-06-16 | Wyeth Corp | Substituted 4-(indazol-3-yl)phenols |
-
2003
- 2003-11-24 MX MXPA05005794A patent/MXPA05005794A/es active IP Right Grant
- 2003-11-24 ES ES03776916T patent/ES2309368T3/es not_active Expired - Lifetime
- 2003-11-24 JP JP2004556171A patent/JP4401298B2/ja not_active Expired - Fee Related
- 2003-11-24 PL PL377609A patent/PL377609A1/pl not_active Application Discontinuation
- 2003-11-24 AU AU2003286180A patent/AU2003286180B2/en not_active Ceased
- 2003-11-24 CN CNB2003801079699A patent/CN100439341C/zh not_active Expired - Fee Related
- 2003-11-24 WO PCT/EP2003/013161 patent/WO2004050634A1/en not_active Ceased
- 2003-11-24 KR KR1020057009878A patent/KR100761562B1/ko not_active Expired - Fee Related
- 2003-11-24 CA CA002507074A patent/CA2507074A1/en not_active Abandoned
- 2003-11-24 EP EP03776916A patent/EP1569911B1/en not_active Expired - Lifetime
- 2003-11-24 BR BR0316950-2A patent/BR0316950A/pt not_active IP Right Cessation
- 2003-11-24 AT AT03776916T patent/ATE399768T1/de not_active IP Right Cessation
- 2003-11-24 DE DE60321958T patent/DE60321958D1/de not_active Expired - Lifetime
- 2003-11-24 RU RU2005120770/04A patent/RU2341518C2/ru not_active IP Right Cessation
- 2003-11-26 TW TW092133163A patent/TW200418816A/zh unknown
- 2003-11-27 PA PA20038589601A patent/PA8589601A1/es unknown
- 2003-11-28 GT GT200300263A patent/GT200300263A/es unknown
- 2003-11-28 AR ARP030104398A patent/AR042148A1/es unknown
- 2003-11-28 UY UY28105A patent/UY28105A1/es not_active Application Discontinuation
- 2003-11-28 PE PE2003001215A patent/PE20040764A1/es not_active Application Discontinuation
- 2003-12-01 US US10/724,971 patent/US7214699B2/en not_active Expired - Fee Related
-
2007
- 2007-05-02 US US11/799,605 patent/US20070213373A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| GT200300263A (es) | 2004-06-28 |
| UY28105A1 (es) | 2004-05-31 |
| JP4401298B2 (ja) | 2010-01-20 |
| US20070213373A1 (en) | 2007-09-13 |
| RU2341518C2 (ru) | 2008-12-20 |
| CN1732158A (zh) | 2006-02-08 |
| WO2004050634A1 (en) | 2004-06-17 |
| KR100761562B1 (ko) | 2007-10-04 |
| EP1569911B1 (en) | 2008-07-02 |
| CN100439341C (zh) | 2008-12-03 |
| CA2507074A1 (en) | 2004-06-17 |
| DE60321958D1 (de) | 2008-08-14 |
| AU2003286180B2 (en) | 2009-11-12 |
| PL377609A1 (pl) | 2006-02-06 |
| AU2003286180A1 (en) | 2004-06-23 |
| PE20040764A1 (es) | 2004-11-06 |
| TW200418816A (en) | 2004-10-01 |
| BR0316950A (pt) | 2006-01-17 |
| RU2005120770A (ru) | 2006-02-10 |
| US7214699B2 (en) | 2007-05-08 |
| US20040110815A1 (en) | 2004-06-10 |
| MXPA05005794A (es) | 2005-08-16 |
| KR20050084079A (ko) | 2005-08-26 |
| JP2006510625A (ja) | 2006-03-30 |
| ES2309368T3 (es) | 2008-12-16 |
| EP1569911A1 (en) | 2005-09-07 |
| PA8589601A1 (es) | 2004-09-16 |
| ATE399768T1 (de) | 2008-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2365588C2 (ru) | Хиназолиновые соединения | |
| RU2005120770A (ru) | Производные индазола, как антагонисты крф | |
| RU2006107438A (ru) | Гмка-ергические модуляторы | |
| RU2009128966A (ru) | Новые производные аминопиримидина в качестве ингибиторов plr1 | |
| MXPA05011710A (es) | Derivados de pirimidina con actividad de crf. | |
| AR060658A1 (es) | Derivados de diceto-piperazina y piperidina como agentes antivirales | |
| AR015595A1 (es) | Compuestos derivados de pirazolo [4,3-d]-pirimidin-7-onas, composiciones farmaceuticas, formulacion veterinaria, uso de dichos compuestos en la preparacionde composicion y formulaciones. procedimientos para su uso, compuestos intermediarios, proceso para la preparacion de los compuestos. | |
| PE20040590A1 (es) | Composiciones de pirrolotriazina anilina como inhibidores de cinasa | |
| ATE390421T1 (de) | Aminoheterocyclen als vr-1 antagonisten zur behandlung von schmerzen | |
| RU2007146390A (ru) | Соединения и композиции в качестве ингибиторов протеинкиназ | |
| DE60322359D1 (de) | Imidazopyridinderivate als kinaseinhibitoren | |
| PA8575401A1 (es) | Derivados de heteroarilamida benzocondensada de tienopiridinas utiles como agentes terapeuticos, composiciones farmaceuticas que incluyen a los mismos y metrodos para su uso | |
| UY28026A1 (es) | 4-piperazinilbencenosulfonilindoles y usos de los mismos. | |
| AR082152A1 (es) | Derivados de n-(metilsulfonil)benzamida, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de nav1.7 | |
| AR034249A1 (es) | Uso de derivados de quinolina como antagonistas alfa-2; compuestos derivados de quinolina y sus composiciones | |
| AR041440A1 (es) | Lactamicos y sus usos | |
| ECSP056115A (es) | ANTAGONISTAS DEL RECEPTOR A2a DE 2-ALQUINIL- Y 2-ALQUENIL-PIRAZOLO-[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PIRIMIDINA ADENOSINA | |
| RU2009103300A (ru) | Производные 2-бензоилимидазопиридинов, их получение и их применение в терапии | |
| AR047537A1 (es) | Piridazinonaureas como antagonistas de integrinas | |
| AR037694A1 (es) | Derivados de pirazol de anillos fusionados, composicion farmaceutica y procedimiento para preparar el compuesto | |
| AR044662A1 (es) | Compuestos de azetidina | |
| AR048691A1 (es) | Compuestos con estructura de alquino con accion antagonista de mch y medicamentos que contienen estos compuestos | |
| AR050698A1 (es) | Compuesto de benzazepina, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento y procedimiento para la preparacion de dicho compuesto | |
| PE20061156A1 (es) | Derivados de benzamida como agentes inhibidores del transportador de glicina | |
| WO2006136837A3 (en) | Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |